N/A N=26 Effect of Increased Free Fatty Acids on Leptin Function
Obesity · Leptin Resistance
Primary: Change in Circulating Glucagon-like Peptide-1 (GLP-1) Levels — 7147; 11725; 11898; 28060 pM*min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=28 Dopamine and Insulin Resistance
Obesity
Primary: Striatal DRD2 Receptor Binding — 28; 33; 32; 33 ratio — p=<0.05
N/A N=60 The Association Between Endometriosis, Obesity and nesfatin1
Endometriosis
Primary: Serum Nesfatin 1 — 190; 510 picogram/millilitre — p=0.05
N/A N=30 Estrogen Sensitivity and Ovulatory Dysfunction in Obesity
Obesity · Infertility
Primary: Luteinizing Hormone Pulse Amplitude — 2.73; 1.12 IU/L
Early Phase 1 N=103 Leptin Infusion and Endothelial Vasomotor Response
Endothelial Dysfunction · Obesity · Vasodilation
Primary: Forearm Blood-flow (FBF) — 1.75; 3.1; NA; NA ml/100 mg tissue/min
N/A N=18 Recombinant Human Leptin Therapy Effects on Insulin Action
Type Two Diabetes Mellitus
Primary: Baseline Glucose Disposal - a Measure of the Body's Ability to Process Sugars. — 14.3; 18.4; 16.7 mmol/kg body weight/minute
Phase 2 N=1 Effects of Leptin Replacement in Children
Obesity · Metabolic Syndrome · Diabetes
Primary: Weight — NA lbs
Phase 2 N=31 Trial of Leptin Administration After Roux-en-Y Gastric Bypass
Overweight
Primary: Weight Change (in kg.) After Each Intervention — -0.39; 0.02 kg weight change
Phase 3 N=15 Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity
Leptin Receptor Deficiency Obesity
Primary: Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal Cohort) — 45.5 percentage of participants — p=0.0001
N/A N=16 The Role of Altered Nutrient Partitioning in Food Reward
Overweight and Obesity
Primary: Change in Preference- Liking — 6.5; 4.5 units on a scale
Phase 2 N=41 Biology and Experience of Eating in Women With Obesity
Obesity
Primary: Number of Participants Who Reported Nausea at 10 Minutes Post Treatment — 17; 18 Participants
N/A N=62 Reproductive Hormonal Alterations in Obesity
Obesity
Primary: Changes in Luteinizing Hormone (LH) Pulse Amplitude (Aim 1) — 4.1; 3.6 IU/L
N/A N=30 Neuroendocrine Modulation of Metabolic Effects in Overweight Adolescents
Obesity
Primary: Peak Growth Hormone (GH) on the GH Stimulation Test — 40.1; 25.2 ng/ml — p=<0.05
N/A N=17 Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome
HIV Lipodystrophy
Primary: Rate of Total Lipolysis — 0.649; 0.767 mmol FFA/kg/h
Phase 3 N=15 Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity
Pro-opiomelanocortin (POMC) Deficiency Obesity
Primary: Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal Cohort) — 80.0 percentage of participants — p=<0.0001
N/A N=38 Mechanisms of Obesity and Its Metabolic Complications in Youth
Obesity, Childhood
Primary: Rate of Appearance of Acetate — 7.40; 7.69; 9.29; 14.7 umol/kg/min
N/A N=56 The Autonomic Nervous System and the Metabolic Syndrome
Obesity
Primary: Insulin Resistance — 3.8; 3.1 mg/kg/min
N/A N=60 Dysregulation of FSH in Obesity: Functional and Statistical Analysis
Obesity · Fertility
Primary: Difference Between Peak Inhibin B — 100.8; 38.8 picograms/mL
N/A N=5 Sympathetic Activation in Obesity
Obesity · Healthy
Primary: Distribution Volume Ratio (DVR) of [11C]MRB PET Imaging of Peripheral Sympathetic Nervous System — 0.13; -0.025; 0.095; -0.03 DVR
N/A N=137 Beige Fat, Energy, and the Natriuretic Peptide System
Obesity
Primary: Adipose Tissue Gene Expression of UCP1 (Uncoupling Protein 1)- Differences by Obesity Status — 7.79; 24.33 fold change — p=<0.01
N/A N=24 Growth Hormone as a Determinant of Weight Regulation
Obesity
Primary: 24 Hour Average Plasma Growth Hormone Concentration — 0.4; 1.2; 4.1 ng/mL
Phase 2 N=24 Leptin in the Maintenance of Reduced Body Weight
Obesity
Primary: Percent Change From Baseline in Body Weight at 6 Months — 10.2; 12.7 percentage change
N/A N=31 Gastrointestinal Hormonal Regulation of Obesity
Obesity
Primary: Change in Body Weight From Baseline to 12 Months — 1.09; 1.55 lbs
N/A N=39 Early-onset Obesity and Cognitive Impairment in Children With Pseudohypoparathyroidism
Pseudohypoparathyroidism · Albright Hereditary Osteodystrophy
Primary: Intelligence Quotient — 85.9; 104.3; 103.2 units on a scale
Phase 1 N=12 In Vivo Leptin Signaling in Humans After Acute Leptin Administration
Lean · Obese · Obese Diabetics
Primary: Leptin Signaling — 3.1 fold change
Phase 3 N=25 Trial of Leptin Replacement Therapy in Patients With Lipodystrophy
Hypoleptinemia · Generalized Lipodystrophy · Partial Lipodystrophy
Primary: Fasting Serum Triglycerides — 203; 304 mg/dL — p=0.2572
Phase 2 N=3 Effects of Human Leptin Replacement
Obesity · Metabolic Syndrome · Diabetes
Primary: Change in Weight — NA lbs
N/A N=112 A Cohort Study of Weight Loss and Gliosis
Obesity, Gliosis, Weight-Loss
Primary: Percent Change in Weight From Baseline — -6.1; -21.2; 1.2 percentage change from baseline — p=<0.001
Phase 3 N=12 Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity
Bardet-Biedl Syndrome · POMC Deficiency Obesity · PCSK1 Deficiency Obesity
Primary: Percentage of Participants With Greater Than or Equal to (≥) 0.2 Reduction of BMI Z-Score From Baseline to Week 52 — 85.7; 80.0 percentage of participants
Phase 3 N=52 Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity
Bardet Biedl Syndrome (BBS) · Alström Syndrome (AS)
Primary: Percentage of Participants (≥12 Years of Age at Baseline) Who Reached ≥10% Weight Loss Threshold After 1 Year (Period 2): Pivotal Cohort — 32.3 percentage of…